Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 2, 2009, Pages 361-364

  Rodríguez, M Mar ^a   Pastor, F Javier ^a   Serena, Carolina ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Amphotericin B; Murine model; Paecilomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENTAL INFECTION; FUNGAL EXAMINATION; FUNGAL LOAD; FUNGAL STRAIN; KIDNEY; LIVER; MALE; MOUSE; MYCOSIS; NONHUMAN; PAECILOMYCES LILACINUS; PAECILOMYCOSIS; SPLEEN; SURVIVAL RATE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; COLONY COUNT, MICROBIAL; KIDNEY; LIVER; MALE; MICE; MYCOSES; PAECILOMYCES; SPLEEN; TRIAZOLES;

EID: 58849098662     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn497     Document Type: Article

References (9)

1. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2006; 12: 948-60.
2. Groll AH, Walsh TJ. Posaconazole: Clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005; 3: 467-87.
3. Mullane K, Toor AA, Kalnicky C et al. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007; 9: 89-96.
4. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, USA, 2002.
5. Ortoneda M, Capilla J, Pastor FJ et al. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004; 50: 247-51.
6. Lozano-Chiu M, Arikan S, Paetznick VL et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999; 43 589-91.
7. Imai JK, Singh G, Clemons KV et al. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48: 4063-6.
8. Nomeir AA, Kumari P, Hilbert MJ et al. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 2000; 44: 727-31.
9. Groll AH, Walsh TJ. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive infections. Mycoses 2006; 49: 7-16.